http://www.cnr.it/ontology/cnr/individuo/prodotto/ID168080

Endocannabinoid signalling in the blood of patients with schizophrenia. (Articolo in rivista)

Type

Label

Endocannabinoid signalling in the blood of patients with schizophrenia. (Articolo in rivista) (literal)

Anno

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

Alternative label

De Marchi N., De Petrocellis L., Orlando P., Daniele F., Fezza F., Di Marzo V. (2003)
Endocannabinoid signalling in the blood of patients with schizophrenia.
in Lipids in health and disease; Biomed Central Ltd., London (Regno Unito)
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

De Marchi N., De Petrocellis L., Orlando P., Daniele F., Fezza F., Di Marzo V. (literal)

Pagina inizio

Pagina fine

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

Rivista

Note

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

Endocannabinoid Research Group, Rochford Hospital, Rochford, United Kingdom South Essex Partnership NHS Trust, Rochford Hospital, Rochford, United Kingdom National Research Council, Institute of Cybernetics, Via Campi Flegrei 34, Pozzuoli (NA), Italy (literal)

Titolo

Endocannabinoid signalling in the blood of patients with schizophrenia. (literal)

Abstract

AIM: To test the hypothesis that schizophrenia might be associated with alterations of the endogenous cannabinoid system in human blood. RESULTS: Blood from 20 healthy volunteers and 12 patients with schizophrenia, 5 of which both before and after a successful antipsychotic treatment, was analysed for: 1) the amounts of the endocannabinoid anandamide; 2) the levels of cannabinoid CB1 and CB2 receptor mRNAs, and 3) the levels of the mRNA encoding the enzyme fatty acid amide hydrolase (FAAH), responsible for anandamide degradation.The amounts of anandamide were significantly higher in the blood of patients with acute schizophrenia than in healthy volunteers (7.79 PlusMinus; 0.50 vs. 2.58 PlusMinus; 0.28 pmol/ml). Clinical remission was accompanied by a significant decrease of the levels of anandamide (3.88 PlusMinus; 0.72 pmol/ml) and of the mRNA transcripts for CB2 receptors and FAAH. CONCLUSION: These findings indicate that endocannabinoid signalling might be altered during the acute phase of schizophrenia not only in the central nervous system but also in the blood. These changes might be related to the several immunological alterations described in schizophrenia. (literal)

Editore